Clinical studies have shown that aprepitant is highly effective in reducing chemotherapy-induced nausea and vomiting (CINV). Its efficacy has been proven in both acute and delayed phases of CINV, making it a valuable addition to antiemetic regimens for cancer patients. The use of aprepitant has significantly improved the quality of life for many patients undergoing chemotherapy.